Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Pregenesys Consensus Meeting held in Cambridge on 13 July 2009 was organized by the Pregenesys Consortium to review and critically discuss current knowledge regarding early markers of preeclampsia, to identify priorities and opportunities for future research, to consider issues that may need to be addressed in future recommendations and to highlight key issues in cost effectiveness and national policies concerning prediction and early screening for the risk of developing preeclampsia. This report summarizes the outcome of the Consensus Meeting and draws attention to issues for further investigation with specific regard to single versus multiple markers, early versus late risk identification, and the long-term effects on both maternal and perinatal health and the need to include these in any future cost-benefit assessment.

More information Original publication

DOI

10.1016/j.placenta.2010.11.022

Type

Journal article

Publication Date

2011-02-01T00:00:00+00:00

Volume

32 Suppl

Pages

S4 - 16

Keywords

Biomarkers, Consensus, Consensus Statements as Topic, Cost-Benefit Analysis, Decision Support Techniques, Diagnostic Techniques, Obstetrical and Gynecological, Early Diagnosis, Female, Health Planning Guidelines, Humans, Models, Biological, Pre-Eclampsia, Pregnancy, Preventive Medicine, Risk Assessment, Trophoblasts